RINVOQ™ (Upadacitinib), approved for the Treatment of Psoriatic Arthritis and Ankylosing Spondylitis
26 Gennaio 2021
The European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and reversible JAK inhibitor for the treatment of active psoriatic arthritis
